Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma 2Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Sunitinib 14aldesleukin 10Bevacizumab 8pembrolizumab 7Nivolumab 7pazopanib 5Axitinib 5atezolizumab 4Interferon-alpha 4sintilimab 3durvalumab 3Sorafenib 3Everolimus 3Cyclophosphamide 3Chemotherapy, Adjuvant 3toripalimab 2sargramostim 2olaparib 2lenvatinib 2fludarabine phosphate 2camrelizumab 2avelumab 2Neoadjuvant Therapy 2Laparoscopy 2Ipilimumab 2Interferon alpha-2 2Immunohistochemistry 2Immune Checkpoint Inhibitors 2Gene Expression Profiling 2Fluorouracil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Renal Cell × keyhole-limpet hemocyanin × Clear all
NCT00093522 2013-12-19

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
28 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡